Portfolio Building Block World Pharma and… (PBPH) Valuation
PBPH valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 47.5 trailing earnings
- Forward P/E
- 17.6 analyst estimates
- Price / sales
- 6.43
- Price / book
- 8.06
- EV / EBITDA
- 15.6
- Earnings yield
- 2.11% inverse of P/E
- Dividend yield
- 1.67% of the holdings
- Return on equity
- 17.0% combined
- Net margin
- 13.5% combined
- Beta
- 0.39 weighted, vs S&P 500
PBPH valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| PBPH | 47.5 | 17.6 | 6.43 | 8.06 | 1.67% | 17.0% | 13.5% | 12.9% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
PBPH valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 96.1% | 47.5 | 17.6 | 6.43 | 8.06 | 1.67% | 17.0% |
PBPH earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How PBPH weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
PBPH largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 16.17% | 42.2 | 24.4 | 14.1 | 0.55% | 27.15% |
| JNJ | Johnson & Johnson | 9.87% | 38.8 | 21.0 | 6.2 | 2.10% | 18.04% |
| ABBV | AbbVie Inc. | 7.38% | 80.6 | 16.4 | 7.8 | 2.42% | 6.49% |
| MRK | Merck & Co., Inc. | 5.20% | 115.8 | 15.3 | 5.4 | 2.33% | 3.18% |
| ROP | Roche Holding AG | 5.19% | — | — | — | — | — |
| AZN | AstraZeneca PLC | 4.67% | — | — | — | — | — |
| AMGN | Amgen Inc. | 4.29% | 26.9 | 16.7 | 6.1 | 2.33% | 11.32% |
| NOVN | Novartis AG | 4.05% | — | — | — | — | — |
| GILD | Gilead Sciences, Inc. | 3.83% | — | 15.6 | 6.4 | 2.10% | −4.60% |
| PFE | Pfizer Inc. | 3.35% | 38.9 | 9.7 | 2.6 | 5.81% | 6.11% |
| VRTX | Vertex Pharmaceuticals Incorporated | 2.58% | 28.9 | 24.1 | 10.1 | — | 6.32% |
| 0QIU | Novo Nordisk A/S Class B | 2.54% | — | — | — | — | — |
| BMY | Bristol-Myers Squibb Company | 2.51% | 13.2 | 9.4 | 2.5 | 4.22% | 13.54% |
| GSK | GSK plc | 1.93% | — | — | — | — | — |
| SAN | Sanofi SA | 1.91% | — | — | — | — | — |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.61% | 19.6 | 14.5 | 5.2 | 0.48% | 5.84% |
| CSL | CSL Ltd | 1.38% | — | — | — | — | — |
| MRNA | Moderna, Inc. | 1.37% | — | 23.0 | 39.1 | — | −3.56% |
| 4502 | Takeda Pharmaceutical Co. Ltd. | 1.24% | — | — | — | — | — |
| NTRA | Natera, Inc. | 1.11% | — | — | 20.9 | — | −0.27% |
| ARGX | Argen-X | 1.10% | — | — | — | — | — |
| BAYN | Bayer AG NA | 0.98% | — | — | — | — | — |
| TEVA | Teva Pharmaceutical Industries Ltd | 0.90% | — | — | — | — | — |
| ILMN | Illumina, Inc. | 0.79% | 49.0 | 40.3 | 8.8 | — | 1.15% |
| SDZ | Sandoz Group AG | 0.79% | — | — | — | — | — |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About PBPH valuation
Adding up its 29 holdings with company data, PBPH trades at 47.5 times trailing earnings and 17.6 times analysts' forward estimates, with a price-to-book ratio of 8.06 and a dividend yield of 1.67%. Its earnings yield of 2.11% is 3.22 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 64.0% of the fund and earn 93.4% of its combined profit. Companies that lost money over the past year are 12.9% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 67.6% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: PBPH chart, PBPH holdings, PBPH dividends.
PBPH valuation FAQ
What is the P/E ratio of PBPH?
Based on its holdings, PBPH has a trailing P/E of 47.5 and a forward P/E of 17.6 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of PBPH?
The trailing earnings yield is 2.11% (1 ÷ P/E) and the forward earnings yield 5.68%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is PBPH more expensive than the S&P 500?
PBPH trades at 47.5 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 17.6 and 19.9.
What is the price-to-book ratio of PBPH?
The holdings of PBPH trade at 8.06 times book value, with a combined return on equity of 17.0%.